Technetium-99m galactosyl-neoglycoalbumin: preparation and preclinical studiesVERA, V. R; STADALNIK, R. C; KROHN, K. A et al.Journal of nuclear medicine. 1985, Vol 26, Num 10, pp 1157-1167, issn 0097-9058Article

Strategies for improving drug development in the early phaseGRIGOLEIT, H.-G.Pharmazeutische Industrie. 1984, Vol 46, Num 5, pp 521-525, issn 0031-711XArticle

Current NCI preclinical antitumor screening in vivo: results of tumor panel screening, 1976-1982, and future directionsVENDITTI, J. M; WESLEY, R. A; PLOWMAN, J et al.Advances in pharmacology and chemotherapy. 1984, Vol 20, pp 1-20, issn 0065-3144Article

The preclinical screening laboratory: evaluation of immunomodulatory and therapeutic properties of biological response modifiersTALMADGE, J. E; HERBERMAN, R. B.Cancer treatment reports. 1986, Vol 70, Num 1, pp 171-182, issn 0361-5960Article

The preclinical new drug research program of the National Cancer Institute = Le programme de recherche préclinique de nouveaux produits du National Cancer InstituteDRISCOLL, J. S.Cancer treatment reports. 1984, Vol 68, Num 1, pp 63-76, issn 0361-5960Article

Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441YAN ZHAO; THOMAS, Huw D; BATEY, Michael A et al.Cancer research (Baltimore). 2006, Vol 66, Num 10, pp 5354-5362, issn 0008-5472, 9 p.Article

PRECLINICAL TOXICOLOGICAL TESTING AND SAFEGUARDS IN CLINICAL TRIALSGRAHAME SMITH DG.1982; EUR. J. CLIN. PHARMACOL.; ISSN 0031-6970; DEU; DA. 1982; VOL. 22; NO 1; PP. 1-6Article

SYMPOSIUM "MOXALACTAM": EXPERIENCE FRANCAISE, EVALUATION PRE-CLINIQUE ET THERAPEUTIQUE, PARIS, LE 27 OCTOBRE 19811983; SEMAINE DES HOPITAUX; ISSN 0037-1777; FRA; DA. 1983; VOL. 59; NO 26; PP. 1943-2004; ABS. ENG; BIBL. DISSEM.Conference Paper

Etoposide (VP-16-213). Current status of an active anticancer drugÓDWYER, P. J; LEYLAND-JONES, B; ALONSO, M. T et al.The New England journal of medicine. 1985, Vol 312, Num 11, pp 692-700, issn 0028-4793Article

Preclinical predictors of clinical safety : Opportunities for improvementSISTARE, F. D; DEGEORGE, J. J.Clinical pharmacology and therapeutics. 2007, Vol 82, Num 2, pp 210-214, issn 0009-9236, 5 p.Article

Abstracts/Research Society on Alcoholism meeting, June 1-5, 1988, Charleston, SC, USAAlcoholism, clinical and experimental research. 1988, Vol 12, Num 2, pp 302-348, issn 0145-6008Conference Proceedings

Preclinical pharmacokinetics of benznidazoleWORKMAN, P; WHITE, R. A. S; WALTON, M. I et al.British journal of cancer. 1984, Vol 50, Num 3, pp 291-303, issn 0007-0920Article

Preclinical restenosis models : Challenges and successesTOUCHARD, Arturo G; SCHWARTZ, Robert S.Toxicologic pathology. 2006, Vol 34, Num 1, pp 11-18, issn 0192-6233, 8 p.Conference Paper

Unresolved issues in combination chemotherapyWITTES, R. E; GOLDIN, A.Cancer treatment reports. 1986, Vol 70, Num 1, pp 105-125, issn 0361-5960Article

Antihyperlipidemic properties of β-pyridylcarbinol. A review of preclinical studiesCOHEN, M.Life sciences (1973). 1985, Vol 37, Num 21, pp 1949-1961, issn 0024-3205Article

Bridging the Gap between Preclinical and Clinical Studies Using Pharmacokinetic-Pharmacodynamic Modeling: An Analysis of GDC-0973, a MEK InhibitorWONG, Harvey; VERNILLET, Laurent; HOEFLICH, Klaus P et al.Clinical cancer research (Print). 2012, Vol 18, Num 11, pp 3090-3099, issn 1078-0432, 10 p.Article

China's unique position in discovery and preclinical researchBOUTELLIER, Roman; ULLMAN, Fredrik.Drug discovery today. 2007, Vol 12, Num 1-2, pp 4-7, issn 1359-6446, 4 p.Article

Preclinical Studies of Celastrol and Acetyl Isogambogic Acid in MelanomaABBAS, Sabiha; BHOUMIK, Anindita; DAHL, Russell et al.Clinical cancer research. 2007, Vol 13, Num 22, pp 6769-6778, issn 1078-0432, 10 p., 1Article

2-D tomography of biotissues images in pre-clinic diagnostics of their pre-cancer statesANGELSKY, O. V; TOMKA, Yu. Ya; USHENKO, A. G et al.SPIE proceedings series. 2005, pp 59720N.1-59720N.5, isbn 0-8194-5991-7, 1VolConference Paper

Preclinical characterisation of ¹¹¹In-DTPA-trastuzumabLUB-DE HOOGE, Marjolijn N; KOSTERINK, Jos G. W; PERIK, Patrick J et al.British journal of pharmacology. 2004, Vol 143, Num 1, pp 99-106, issn 0007-1188, 8 p.Article

A postgraduate course in preclinical drug evaluationATKINSON, Jeffrey.Thérapie (Paris). 2004, Vol 59, Num 1, pp 61-62, issn 0040-5957, 2 p.Conference Paper

Design, synthesis and preclinical evaluation of radiolabeled peptides for diagnosis and therapyALOJ, L; MORELLI, G.Current pharmaceutical design. 2004, Vol 10, Num 24, pp 3009-3031, issn 1381-6128, 23 p.Article

Outsourcing outlook: Gene logic looks to integrate genomics into preclinical testingMILLER, Jim.Pharmaceutical technology (2003). 2003, Vol 27, Num 6, pp 74-76, issn 1543-2521, 2 p.Article

The thymosins: preclinical and clinical studies with fraction V and alpha-I = Les thymosines: études précliniques et cliniques de la fraction V et alpha-1SMALLEY, R. V; TALMADGE, J; OLDHAM, R. K et al.Cancer treatment reviews. 1984, Vol 11, Num 1, pp 69-84, issn 0305-7372Article

Preclinical Evidence That PD1 Blockade Cooperates with Cancer Vaccine TEGVAX to Elicit Regression of Established TumorsJUAN FU; MALM, Ian-James; KADAYAKKARA, Deepak K et al.Cancer research (Chicago, Ill.). 2014, Vol 74, Num 15, pp 4042-4052, issn 0008-5472, 11 p.Article